97
Views
2
CrossRef citations to date
0
Altmetric
Commentary

Antiviral treatment of HBV positive pregnant women: an additional tool to reduce perinatal transmission

, &

References

  • Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324–2334. DOI:10.1056/NEJMoa1508660.
  • Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; March 2015. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1
  • Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;(16) 1399–1408. DOI:10.1016/S1473-3099(16)30204-3.
  • Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis. 2016 Jun;62(12):1604–1609.10.1093/cid/ciw159
  • Brown RS Jr, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the antiretroviral pregnancy registry. J Hepatol. 2012;57:953–959.10.1016/j.jhep.2012.06.031
  • Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014;65:33–41.10.1097/QAI.0b013e3182a921eb
  • Palombi L, Pirillo MF, Marchei E, Jere H, Sagno JB, Luhanga R, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. J Antimicrob Chemother. 2016;71(4):1027–1030.10.1093/jac/dkv435
  • Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016 Aug;16(1): 393–398.10.1186/s12879-016-1734-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.